Literature DB >> 22727081

Association between enhanced screening for Chlamydia trachomatis and Neisseria gonorrhoeae and reductions in sequelae among women.

Greta L Anschuetz1, Lenore Asbel, C Victor Spain, Melinda Salmon, Felicia Lewis, E Claire Newbern, Martin Goldberg, Caroline C Johnson.   

Abstract

PURPOSE: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) are typically asymptomatic, but, if untreated, can lead to sequelae including pelvic inflammatory disease (PID) and ectopic pregnancy. The objective was to describe trends of these sequelae in Philadelphia after implementing citywide screening in a high-morbidity population (>6% positivity).
METHODS: In this ecologic study, which used data from 1996 to 2007, multivariable linear regression analysis was used to assess the association between the number of annual CT/GC screening tests by gender and the number of women aged 14-30 years hospitalized for PID or ectopic pregnancy. A standardized hospitalization database provided the number of admissions with a discharge diagnosis of PID or ectopic pregnancy. Positive CT/GC laboratory results reported by hospitals and emergency departments (EDs) were used as a proxy for outpatient PID.
RESULTS: Between 1996 and 2007, CT/GC screening increased by 188%, whereas declines were noted in hospitalized PID cases (36%, -173 cases), ectopic pregnancy (38%, -119 cases), and ED-diagnosed CT/GC cases (39%, -727 cases). Screening 10,000 females for CT/GC corresponded with 26.1 fewer hospitalized PID cases (95% confidence interval 11.2-41.1), whereas screening 10,000 males corresponded to 10.4 (95% CI: 2.6-18.2) fewer cases. Although male screening was not significantly associated with ectopic pregnancy, screening 10,000 females was associated with 28.6 fewer ectopic pregnancies (95% CI: 7.4-49.8).
CONCLUSIONS: This ecologic analysis found a correlation between large-scale CT/GC screening in a high-morbidity population and reductions in hospitalized PID, ectopic pregnancies, and ED-diagnosed CT/GC.
Copyright © 2012 Society for Adolescent Health and Medicine. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22727081     DOI: 10.1016/j.jadohealth.2011.11.002

Source DB:  PubMed          Journal:  J Adolesc Health        ISSN: 1054-139X            Impact factor:   5.012


  6 in total

1.  Microbiological Characteristics of Chlamydia trachomatis and Neisseria gonorrhoeae Infections in South African Women.

Authors:  Jan Henk Dubbink; Dewi J de Waaij; Myrte Bos; Lisette van der Eem; Cécile Bébéar; Nontembeko Mbambazela; Sander Ouburg; Remco P H Peters; Servaas A Morré
Journal:  J Clin Microbiol       Date:  2015-10-28       Impact factor: 5.948

Review 2.  Gonorrhea Control, United States, 1972-2015, A Narrative Review.

Authors:  Thomas A Peterman; Kevin O'Connor; Heather M Bradley; Elizabeth A Torrone; Kyle T Bernstein
Journal:  Sex Transm Dis       Date:  2016-12       Impact factor: 2.830

3.  Steroids alone or as adjunctive therapy with doxycycline fail to improve oviduct damage in mice infected with Chlamydia muridarum.

Authors:  Tammy E Corr; Jeanne Sullivan; Lauren C Frazer; Charles W Andrews; Catherine M O'Connell; Toni Darville
Journal:  Clin Vaccine Immunol       Date:  2014-04-02

4.  Screening for asymptomatic chlamydia and gonorrhea in adolescent males in an urban pediatric emergency department.

Authors:  Megan E Maraynes; Jennifer H Chao; Konstantinos Agoritsas; Richard Sinert; Shahriar Zehtabchi
Journal:  World J Clin Pediatr       Date:  2017-08-08

5.  Pelvic Inflammatory Disease Trends Among Emergency Department Visits in North Carolina, 2008 to 2017.

Authors:  Dayna T Neo; Erika Samoff; Anna Cope
Journal:  Sex Transm Dis       Date:  2022-01-01       Impact factor: 2.830

6.  Prevalence of 7 sexually transmitted organisms by multiplex real-time PCR in Fallopian tube specimens collected from Saudi women with and without ectopic pregnancy.

Authors:  Ahmed Mohamed Ashshi; Sarah Abdullah Batwa; Seham Yahia Kutbi; Faizah Ahmed Malibary; Mohamed Batwa; Bassem Refaat
Journal:  BMC Infect Dis       Date:  2015-12-15       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.